Intralymphatic Immunotherapy: Update and Unmet Needs
Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT...
Gespeichert in:
| Veröffentlicht in: | International archives of allergy and immunology 2019-01, Vol.178 (2), p.141-149 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 149 |
|---|---|
| container_issue | 2 |
| container_start_page | 141 |
| container_title | International archives of allergy and immunology |
| container_volume | 178 |
| creator | Senti, Gabriela Freiburghaus, Andreas U. Larenas-Linnemann, Désirée Hoffmann, Hans Jürgen Patterson, Amber M. Klimek, Ludger Di Bona, Danilo Pfaar, Oliver Ahlbeck, Lars Akdis, Mübeccel Weinfeld, Dan Contreras-Verduzco, Francisco A. Pedroza-Melendez, Alvaro Skaarup, Søren H. Lee, Sang Min Cardell, Lars-Olaf Schmid, Johannes M. Westin, Ulla Dollner, Ralph Kündig, Thomas M. |
| description | Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes – intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations. |
| doi_str_mv | 10.1159/000493647 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_swepu</sourceid><recordid>TN_cdi_gale_healthsolutions_A630939880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A630939880</galeid><sourcerecordid>A630939880</sourcerecordid><originalsourceid>FETCH-LOGICAL-c659t-75b1d1a1553a0881d0b6788f20294707fb8c1f35191912961b95a4bd9566e1e3</originalsourceid><addsrcrecordid>eNp90k1v1DAQBuAIgWgpHLgjtBISgkPKOP6IzS0qXytVcGm5Wk482TVN4tROhPbf4yrbLZUK8sGW9cw4bzRZ9pLAKSFcfQAApqhg5aPsmLCC5gCqfJzOQGReMCqPsmcx_gJIWIqn2REFqoji7Dhj62EKptv149ZMrlmt-34e_LTFYMbdx9XlaM2EKzPY1eXQ47T6jmjj8-xJa7qIL_b7SXbx5fPF2bf8_MfX9Vl1njeCqykveU0sMYRzakBKYqEWpZRtAYViJZRtLRvSUk7St5BCCVIrblhtFRcCCdKTLF_axt84zrUeg-tN2GlvnN5fXaUTaiZTRpG8-qcfg7d3RbeFhAGlREHx37c-uZ-V9mGjOzdrwpmgNPl3i0-Nr2eMk-5dbLDrzIB-jrogFCDlKGWibxa6MR1qN7Q-_fHmhutKUFBUSQlJnT6g0rLYu8YP2Lp0f6_g7V8FWzTdtI2-myfnh3gfvl9gE3yMAdtDOAL6Zn70YX6Sfb2PNdc92oO8HZi7MFcmbDAcwLqqlhZ6tG1Srx5U-1f-ALYJ0Qc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2130056678</pqid></control><display><type>article</type><title>Intralymphatic Immunotherapy: Update and Unmet Needs</title><source>SWEPUB Freely available online</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Senti, Gabriela ; Freiburghaus, Andreas U. ; Larenas-Linnemann, Désirée ; Hoffmann, Hans Jürgen ; Patterson, Amber M. ; Klimek, Ludger ; Di Bona, Danilo ; Pfaar, Oliver ; Ahlbeck, Lars ; Akdis, Mübeccel ; Weinfeld, Dan ; Contreras-Verduzco, Francisco A. ; Pedroza-Melendez, Alvaro ; Skaarup, Søren H. ; Lee, Sang Min ; Cardell, Lars-Olaf ; Schmid, Johannes M. ; Westin, Ulla ; Dollner, Ralph ; Kündig, Thomas M.</creator><creatorcontrib>Senti, Gabriela ; Freiburghaus, Andreas U. ; Larenas-Linnemann, Désirée ; Hoffmann, Hans Jürgen ; Patterson, Amber M. ; Klimek, Ludger ; Di Bona, Danilo ; Pfaar, Oliver ; Ahlbeck, Lars ; Akdis, Mübeccel ; Weinfeld, Dan ; Contreras-Verduzco, Francisco A. ; Pedroza-Melendez, Alvaro ; Skaarup, Søren H. ; Lee, Sang Min ; Cardell, Lars-Olaf ; Schmid, Johannes M. ; Westin, Ulla ; Dollner, Ralph ; Kündig, Thomas M.</creatorcontrib><description>Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes – intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.</description><identifier>ISSN: 1018-2438</identifier><identifier>ISSN: 1423-0097</identifier><identifier>EISSN: 1423-0097</identifier><identifier>DOI: 10.1159/000493647</identifier><identifier>PMID: 30391954</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Allergen-specific immunotherapy ; Allergy ; Care and treatment ; Clinical Allergy – Review Article ; Clinical trials ; Comparative analysis ; Drug delivery systems ; Immunotherapy ; Intralymphatic immunotherapy ; Medicin och hälsovetenskap ; Methods</subject><ispartof>International archives of allergy and immunology, 2019-01, Vol.178 (2), p.141-149</ispartof><rights>2018 S. Karger AG, Basel</rights><rights>2018 S. Karger AG, Basel.</rights><rights>COPYRIGHT 2019 S. Karger AG</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c659t-75b1d1a1553a0881d0b6788f20294707fb8c1f35191912961b95a4bd9566e1e3</citedby><cites>FETCH-LOGICAL-c659t-75b1d1a1553a0881d0b6788f20294707fb8c1f35191912961b95a4bd9566e1e3</cites><orcidid>0000-0002-6743-7931 ; 0000-0003-4374-9639</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,554,782,786,887,2431,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30391954$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-154633$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:140331902$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Senti, Gabriela</creatorcontrib><creatorcontrib>Freiburghaus, Andreas U.</creatorcontrib><creatorcontrib>Larenas-Linnemann, Désirée</creatorcontrib><creatorcontrib>Hoffmann, Hans Jürgen</creatorcontrib><creatorcontrib>Patterson, Amber M.</creatorcontrib><creatorcontrib>Klimek, Ludger</creatorcontrib><creatorcontrib>Di Bona, Danilo</creatorcontrib><creatorcontrib>Pfaar, Oliver</creatorcontrib><creatorcontrib>Ahlbeck, Lars</creatorcontrib><creatorcontrib>Akdis, Mübeccel</creatorcontrib><creatorcontrib>Weinfeld, Dan</creatorcontrib><creatorcontrib>Contreras-Verduzco, Francisco A.</creatorcontrib><creatorcontrib>Pedroza-Melendez, Alvaro</creatorcontrib><creatorcontrib>Skaarup, Søren H.</creatorcontrib><creatorcontrib>Lee, Sang Min</creatorcontrib><creatorcontrib>Cardell, Lars-Olaf</creatorcontrib><creatorcontrib>Schmid, Johannes M.</creatorcontrib><creatorcontrib>Westin, Ulla</creatorcontrib><creatorcontrib>Dollner, Ralph</creatorcontrib><creatorcontrib>Kündig, Thomas M.</creatorcontrib><title>Intralymphatic Immunotherapy: Update and Unmet Needs</title><title>International archives of allergy and immunology</title><addtitle>Int Arch Allergy Immunol</addtitle><description>Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes – intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.</description><subject>Allergen-specific immunotherapy</subject><subject>Allergy</subject><subject>Care and treatment</subject><subject>Clinical Allergy – Review Article</subject><subject>Clinical trials</subject><subject>Comparative analysis</subject><subject>Drug delivery systems</subject><subject>Immunotherapy</subject><subject>Intralymphatic immunotherapy</subject><subject>Medicin och hälsovetenskap</subject><subject>Methods</subject><issn>1018-2438</issn><issn>1423-0097</issn><issn>1423-0097</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>D8T</sourceid><recordid>eNp90k1v1DAQBuAIgWgpHLgjtBISgkPKOP6IzS0qXytVcGm5Wk482TVN4tROhPbf4yrbLZUK8sGW9cw4bzRZ9pLAKSFcfQAApqhg5aPsmLCC5gCqfJzOQGReMCqPsmcx_gJIWIqn2REFqoji7Dhj62EKptv149ZMrlmt-34e_LTFYMbdx9XlaM2EKzPY1eXQ47T6jmjj8-xJa7qIL_b7SXbx5fPF2bf8_MfX9Vl1njeCqykveU0sMYRzakBKYqEWpZRtAYViJZRtLRvSUk7St5BCCVIrblhtFRcCCdKTLF_axt84zrUeg-tN2GlvnN5fXaUTaiZTRpG8-qcfg7d3RbeFhAGlREHx37c-uZ-V9mGjOzdrwpmgNPl3i0-Nr2eMk-5dbLDrzIB-jrogFCDlKGWibxa6MR1qN7Q-_fHmhutKUFBUSQlJnT6g0rLYu8YP2Lp0f6_g7V8FWzTdtI2-myfnh3gfvl9gE3yMAdtDOAL6Zn70YX6Sfb2PNdc92oO8HZi7MFcmbDAcwLqqlhZ6tG1Srx5U-1f-ALYJ0Qc</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Senti, Gabriela</creator><creator>Freiburghaus, Andreas U.</creator><creator>Larenas-Linnemann, Désirée</creator><creator>Hoffmann, Hans Jürgen</creator><creator>Patterson, Amber M.</creator><creator>Klimek, Ludger</creator><creator>Di Bona, Danilo</creator><creator>Pfaar, Oliver</creator><creator>Ahlbeck, Lars</creator><creator>Akdis, Mübeccel</creator><creator>Weinfeld, Dan</creator><creator>Contreras-Verduzco, Francisco A.</creator><creator>Pedroza-Melendez, Alvaro</creator><creator>Skaarup, Søren H.</creator><creator>Lee, Sang Min</creator><creator>Cardell, Lars-Olaf</creator><creator>Schmid, Johannes M.</creator><creator>Westin, Ulla</creator><creator>Dollner, Ralph</creator><creator>Kündig, Thomas M.</creator><general>S. Karger AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DG8</scope><scope>D8T</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0002-6743-7931</orcidid><orcidid>https://orcid.org/0000-0003-4374-9639</orcidid></search><sort><creationdate>20190101</creationdate><title>Intralymphatic Immunotherapy: Update and Unmet Needs</title><author>Senti, Gabriela ; Freiburghaus, Andreas U. ; Larenas-Linnemann, Désirée ; Hoffmann, Hans Jürgen ; Patterson, Amber M. ; Klimek, Ludger ; Di Bona, Danilo ; Pfaar, Oliver ; Ahlbeck, Lars ; Akdis, Mübeccel ; Weinfeld, Dan ; Contreras-Verduzco, Francisco A. ; Pedroza-Melendez, Alvaro ; Skaarup, Søren H. ; Lee, Sang Min ; Cardell, Lars-Olaf ; Schmid, Johannes M. ; Westin, Ulla ; Dollner, Ralph ; Kündig, Thomas M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c659t-75b1d1a1553a0881d0b6788f20294707fb8c1f35191912961b95a4bd9566e1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Allergen-specific immunotherapy</topic><topic>Allergy</topic><topic>Care and treatment</topic><topic>Clinical Allergy – Review Article</topic><topic>Clinical trials</topic><topic>Comparative analysis</topic><topic>Drug delivery systems</topic><topic>Immunotherapy</topic><topic>Intralymphatic immunotherapy</topic><topic>Medicin och hälsovetenskap</topic><topic>Methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Senti, Gabriela</creatorcontrib><creatorcontrib>Freiburghaus, Andreas U.</creatorcontrib><creatorcontrib>Larenas-Linnemann, Désirée</creatorcontrib><creatorcontrib>Hoffmann, Hans Jürgen</creatorcontrib><creatorcontrib>Patterson, Amber M.</creatorcontrib><creatorcontrib>Klimek, Ludger</creatorcontrib><creatorcontrib>Di Bona, Danilo</creatorcontrib><creatorcontrib>Pfaar, Oliver</creatorcontrib><creatorcontrib>Ahlbeck, Lars</creatorcontrib><creatorcontrib>Akdis, Mübeccel</creatorcontrib><creatorcontrib>Weinfeld, Dan</creatorcontrib><creatorcontrib>Contreras-Verduzco, Francisco A.</creatorcontrib><creatorcontrib>Pedroza-Melendez, Alvaro</creatorcontrib><creatorcontrib>Skaarup, Søren H.</creatorcontrib><creatorcontrib>Lee, Sang Min</creatorcontrib><creatorcontrib>Cardell, Lars-Olaf</creatorcontrib><creatorcontrib>Schmid, Johannes M.</creatorcontrib><creatorcontrib>Westin, Ulla</creatorcontrib><creatorcontrib>Dollner, Ralph</creatorcontrib><creatorcontrib>Kündig, Thomas M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Linköpings universitet</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>International archives of allergy and immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Senti, Gabriela</au><au>Freiburghaus, Andreas U.</au><au>Larenas-Linnemann, Désirée</au><au>Hoffmann, Hans Jürgen</au><au>Patterson, Amber M.</au><au>Klimek, Ludger</au><au>Di Bona, Danilo</au><au>Pfaar, Oliver</au><au>Ahlbeck, Lars</au><au>Akdis, Mübeccel</au><au>Weinfeld, Dan</au><au>Contreras-Verduzco, Francisco A.</au><au>Pedroza-Melendez, Alvaro</au><au>Skaarup, Søren H.</au><au>Lee, Sang Min</au><au>Cardell, Lars-Olaf</au><au>Schmid, Johannes M.</au><au>Westin, Ulla</au><au>Dollner, Ralph</au><au>Kündig, Thomas M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intralymphatic Immunotherapy: Update and Unmet Needs</atitle><jtitle>International archives of allergy and immunology</jtitle><addtitle>Int Arch Allergy Immunol</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>178</volume><issue>2</issue><spage>141</spage><epage>149</epage><pages>141-149</pages><issn>1018-2438</issn><issn>1423-0097</issn><eissn>1423-0097</eissn><abstract>Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes – intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>30391954</pmid><doi>10.1159/000493647</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6743-7931</orcidid><orcidid>https://orcid.org/0000-0003-4374-9639</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1018-2438 |
| ispartof | International archives of allergy and immunology, 2019-01, Vol.178 (2), p.141-149 |
| issn | 1018-2438 1423-0097 1423-0097 |
| language | eng |
| recordid | cdi_gale_healthsolutions_A630939880 |
| source | SWEPUB Freely available online; Karger Journals; Alma/SFX Local Collection |
| subjects | Allergen-specific immunotherapy Allergy Care and treatment Clinical Allergy – Review Article Clinical trials Comparative analysis Drug delivery systems Immunotherapy Intralymphatic immunotherapy Medicin och hälsovetenskap Methods |
| title | Intralymphatic Immunotherapy: Update and Unmet Needs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T07%3A53%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intralymphatic%20Immunotherapy:%20Update%20and%20Unmet%20Needs&rft.jtitle=International%20archives%20of%20allergy%20and%20immunology&rft.au=Senti,%20Gabriela&rft.date=2019-01-01&rft.volume=178&rft.issue=2&rft.spage=141&rft.epage=149&rft.pages=141-149&rft.issn=1018-2438&rft.eissn=1423-0097&rft_id=info:doi/10.1159/000493647&rft_dat=%3Cgale_swepu%3EA630939880%3C/gale_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2130056678&rft_id=info:pmid/30391954&rft_galeid=A630939880&rfr_iscdi=true |